US20130039882A1 - Method to mitigate injury from radiation exposure - Google Patents
Method to mitigate injury from radiation exposure Download PDFInfo
- Publication number
- US20130039882A1 US20130039882A1 US13/504,585 US201013504585A US2013039882A1 US 20130039882 A1 US20130039882 A1 US 20130039882A1 US 201013504585 A US201013504585 A US 201013504585A US 2013039882 A1 US2013039882 A1 US 2013039882A1
- Authority
- US
- United States
- Prior art keywords
- radiation
- exposure
- radiation exposure
- injury
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 14
- 230000006378 damage Effects 0.000 title claims abstract description 14
- 208000014674 injury Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 19
- 230000005855 radiation Effects 0.000 claims abstract description 30
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims abstract description 16
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims abstract description 15
- 230000000116 mitigating effect Effects 0.000 claims abstract description 8
- 241000124008 Mammalia Species 0.000 claims abstract 5
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 39
- 229960002169 plerixafor Drugs 0.000 claims description 33
- 210000000056 organ Anatomy 0.000 claims description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 description 16
- 210000000130 stem cell Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 206010040844 Skin exfoliation Diseases 0.000 description 8
- 208000019155 Radiation injury Diseases 0.000 description 7
- 230000035618 desquamation Effects 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 231100000225 lethality Toxicity 0.000 description 6
- 229940074923 mozobil Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000037380 skin damage Effects 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007775 late Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- UEUPDYPUTTUXLJ-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride Chemical class Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 UEUPDYPUTTUXLJ-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000017323 hematopoietic stem cell migration to bone marrow Effects 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- tissue/organ injury results in part because of a loss of stem cells.
- Peripheral blood stem cell mobilization which has become extremely important as a source of hematopoietic stem cells for bone marrow transplantation over the last 15 years, is generally performed using the cytokine drug, G-CSF, but is ineffective in around 15 to 20% of patients. Other agents have been used to mobilize and enhance G-CSF-induced mobilization.
- the stem cell factor was investigated, but was withdrawn from clinical development due to its toxicity.
- some embodiments comprise methods to mitigate injury from radiation exposure, including without limitation, in humans.
- CXCR4 antagonist mitigates injury to skin and perhaps other tissue/organs after radiation exposure.
- FIG. 1 is a graphical representation of test results from Example 2.
- FIG. 2A is a graphical representation and photographic depiction of test results from Example 3A.
- FIG. 2B is a graphical representation and photographic depiction of test results from Example 3B.
- FIG. 3 is a graphical representation of test results from Example 4.
- CXCR4 antagonist mitigated radiation injury of mice following irradiation.
- the antagonist was given starting one week after the radiation exposure. This effect may result from mobilization of stem cells, thus mitigating organ/tissue injury following radiation exposure.
- AMD-3100 developed for use in the treatment of HIV, mobilizes stem cells from bone marrow niches. It has been established in the scientific literature that AMD-3100 mitigates lethality after total body irradiation in dogs. We hypothesized and experimentally verified that AMD-3100 mitigates radiation injury following localized skin irradiation, and it may mitigate radiation injury to other organs using this or a similar approach.
- AMD-3100 Use of AMD-3100 to mitigate the bone marrow syndrome after total body irradiation (TBI) is very limited.
- Other workers have shown that both autologous and allogeneic AMD-3100 mobilized peripheral blood mononuclear cells led to prompt and durable engraftment in dogs after lethal dose of TBI.
- Pharmacokinetic experiments demonstrated a rapid peak and subsequent clearance of the drug within 24 h of injection. Median days to neutrophil and platelet recoveries were 9 and 25 days, respectively. AMD-3100 administration to dogs was well tolerated without noticeable adverse effects.
- AMD-3100 is a bicyclam derivative, initially developed for potential use in the treatment of HIV for its role in the blocking CXCR4, a chemokine receptor which acts as a co-receptor for certain strains of HIV.
- CXCR4 alpha-chemokine receptor and its ligand SDF-1 are also important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence.
- the compound has been found to be a strong inducer of “mobilization” of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells in mice, dogs, and humans.
- AMD-3100 could mobilize hematopoietic progenitor cells from marrow to peripheral blood in healthy human volunteers.
- HPC human hematopoietic progenitor cells
- the CXCR4 antagonist is safe in humans at the dose that produces an effect.
- Mozobil also known as plerixafor or AMD-3100, a CXCR4 antagonist, when the drug was applied days or even one week after the radiation exposure.
- mice We exposed mice to radiation, total body dose of 8 Gy at a rate of approximately 1 Gy per minute. Subsequently, days later, we administered Mozobil [I.P.] at 5 mg/kg dose as a single injection. We monitored the test mice for lethality. We found survival was significantly enhanced with Mozobil.
- FIG. 1 illustrates the significant enhancement in survival to an otherwise lethal radiation exposure when plerixafor was administered 3 days after the radiation.
- mice We exposed the legs of mice to 25 or 30 Gy radiation at a dose rate of approximately 5 Gy per minute. Subsequently, one week later, we administered Mozobil [LP.] at 5 mg/kg dose followed by another Mozobil administration [5 mg/kg, I.P.] 48 hours later. We monitored the test mice for lesions relating to skin damage. We found skin damage was significantly reduced in mice receiving Mozobil.
- Plerixafor given 7 days after the radiation exposure was highly effective at mitigating radiation cutaneous injury.
- a radiation exposure of 25 Gy caused chronic cutaneous injury characterized by dry desquamation and minimal scabbing that started at about 3 weeks and persisted to 60 days.
- plerixafor (5 mg/kg, I.P.) given twice starting one week after the radiation exposure followed by another dose 48 hours later, eighteen days after radiation the reaction was initially similar to radiation alone and soon resolved completely such that the legs were normal except for some hair thinning at day 60.
- FIG. 2A illustrates the effect at one month after 25 Gy exposure with and without plerixafor.
- mice receiving 30 Gy plus plerixafor had some hair loss but were otherwise normal at approximately day 60.
- Examples 3A and 3B illustrate the mitigating effect of plerixafor as a function of time using the semi-quantitative scale of skin reaction described in Table 1.
- RPF radiation “protection” factor
- CXCR4 Antagonist Reduces TGF-beta and TNF-alpha in Irradiated Skin
- the magnitude of the effect was estimated.
- tissue such as bone marrow, skin and gastrointestinal tract are likely to benefit. This is significant because these tissues are known to be particularly susceptible to radiation injury. Other tissues which are slowly proliferating tissues such as lung and brain in which function can be preserved by a functioning subunit may be reconstituted by mobilized stem cells may also benefit from the approach.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Mitigating radiation induced injury to a mammal that has been exposed to radiation by administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.
Description
- This application claims the benefit of U.S. provisional patent application Ser. No. 61/255,619, filed Oct. 28, 2009.
- Following a (terrorist, accident, or during radiation therapy for cancer) radiation exposure either to the whole body or localized to a region of the body, tissue/organ injury results in part because of a loss of stem cells.
- Peripheral blood stem cell mobilization, which has become extremely important as a source of hematopoietic stem cells for bone marrow transplantation over the last 15 years, is generally performed using the cytokine drug, G-CSF, but is ineffective in around 15 to 20% of patients. Other agents have been used to mobilize and enhance G-CSF-induced mobilization. The stem cell factor was investigated, but was withdrawn from clinical development due to its toxicity.
- There is a need to develop pharmacologic agents that can reduce late tissue injury including skin in the time after a radiation exposure.
- Without limiting the invention to only those embodiments expressly disclosed herein and without disclaiming any embodiments, some embodiments comprise methods to mitigate injury from radiation exposure, including without limitation, in humans.
- We have demonstrated that CXCR4 antagonist mitigates injury to skin and perhaps other tissue/organs after radiation exposure.
-
FIG. 1 is a graphical representation of test results from Example 2. -
FIG. 2A is a graphical representation and photographic depiction of test results from Example 3A. -
FIG. 2B is a graphical representation and photographic depiction of test results from Example 3B. -
FIG. 3 is a graphical representation of test results from Example 4. - We have discovered unexpectedly that in some embodiments, without limitation, CXCR4 antagonist mitigated radiation injury of mice following irradiation. Of note, the antagonist was given starting one week after the radiation exposure. This effect may result from mobilization of stem cells, thus mitigating organ/tissue injury following radiation exposure.
- To our knowledge, no other mitigator of radiation injury has been shown to be effective when started after the radiation exposure particularly when started one week after.
- Among CXCR4 antagonists, AMD-3100, developed for use in the treatment of HIV, mobilizes stem cells from bone marrow niches. It has been established in the scientific literature that AMD-3100 mitigates lethality after total body irradiation in dogs. We hypothesized and experimentally verified that AMD-3100 mitigates radiation injury following localized skin irradiation, and it may mitigate radiation injury to other organs using this or a similar approach.
- Use of AMD-3100 to mitigate the bone marrow syndrome after total body irradiation (TBI) is very limited. Other workers have shown that both autologous and allogeneic AMD-3100 mobilized peripheral blood mononuclear cells led to prompt and durable engraftment in dogs after lethal dose of TBI. Pharmacokinetic experiments demonstrated a rapid peak and subsequent clearance of the drug within 24 h of injection. Median days to neutrophil and platelet recoveries were 9 and 25 days, respectively. AMD-3100 administration to dogs was well tolerated without noticeable adverse effects.
- AMD-3100 is a bicyclam derivative, initially developed for potential use in the treatment of HIV for its role in the blocking CXCR4, a chemokine receptor which acts as a co-receptor for certain strains of HIV. However, the CXCR4 alpha-chemokine receptor and its ligand SDF-1 are also important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. The compound has been found to be a strong inducer of “mobilization” of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells in mice, dogs, and humans. Other workers have shown that AMD-3100 could mobilize hematopoietic progenitor cells from marrow to peripheral blood in healthy human volunteers. The side effects of single-dose administration AMD-3100 to normal donors were very minor. They also showed that AMD-3100 induced rapid mobilization of mouse and human hematopoietic progenitor cells (HPC) and more importantly synergistically augmented G-CSF-induced mobilization of HPCs. Further, AMD-3100 mobilized peripheral-blood mononuclear cells were successfully engrafted to produce long-term repopulating cells.
- The CXCR4 antagonist is safe in humans at the dose that produces an effect.
- The development of an effective mitigator of radiation tissue/organ injury following a radiation exposure, such as CXCR4 antagonist, has the potential to benefit at least three distinct groups of individuals: (1) victims in the unfortunate event of a radiological attack or nuclear disaster; (2) clean up workers following these events; and (3) patients undergoing radiation therapy. With the former there is the additional requirement that the mitigator has its effect when administered after the radiation exposure since there may be a lack of prior knowledge of a radiological incident. In particular, use of stem cell mobilizers according to some embodiments in cancer patients undergoing radiation therapy may be substantial since the compound could potentially be administered after the tumor has been effectively treated. There are about half a million cancer patients that receive radiation therapy annually; a significant fraction of these patients receive a substantial radiation dose to normal skin tissue. There may be tens of thousands of individuals that would benefit from the effects of stem cell mobilizers to reduce the late effects of radiation on normal tissues such as skin tissue.
- The following examples of some embodiments of the invention are provided without limiting the invention to only those embodiments described herein and without disclaiming any embodiments.
- We have demonstrated that radiation injury can be reduced significantly by Mozobil, also known as plerixafor or AMD-3100, a CXCR4 antagonist, when the drug was applied days or even one week after the radiation exposure.
- We exposed mice to radiation, total body dose of 8 Gy at a rate of approximately 1 Gy per minute. Subsequently, days later, we administered Mozobil [I.P.] at 5 mg/kg dose as a single injection. We monitored the test mice for lethality. We found survival was significantly enhanced with Mozobil.
- The CXCR4 antagonist plerixafor, given after total body irradiation (TBI) to C57BL/6 mice provides significant mitigation from TBI-induced lethality.
FIG. 1 illustrates the significant enhancement in survival to an otherwise lethal radiation exposure when plerixafor was administered 3 days after the radiation. - Referring to
FIG. 1 , mitigation of radiation lethality by plerixafor, 5 mg/kg, I.P. increased with the duration of time delay between radiation exposure and drug administration. Survival at 30 days increased from 0% to 14% to 69% when plerixafor was administered 24 h, 48 h, and 72 h after radiation exposure, respectively. Median survival was significantly improved from 18 to beyond 30 days, when the time between radiation and drug increased from 48 to 72 h (p<0.01, Logrank). - We note that the enhanced survival after radiation of animals given plerixafor was consistent with the observation that mice exposed to a sublethal dose, 6.5 Gy TBI for C57BL/6 mice, had improved bone marrow cell survival 12 days after the radiation exposure. The number of endogenous spleen colonies was increased from a mean of 10±3 in C57BL/6 mice receiving a sublethal radiation dose of 6.5 Gy TBI (n=8) to a mean of 47±9 in mice given plerixafor (n=8), 5 mg/kg, 72 h after the radiation.
- The survival results were confirmed in a different animal strain. Median survival of Balb/c mice improved from 13 days for mice receiving 7 Gy radiation alone to 18 days for mice receiving plerixafor, 5 mg/kg, i.p., 24 hours after 7 Gy (p<0.01, Logrank).
- We exposed the legs of mice to 25 or 30 Gy radiation at a dose rate of approximately 5 Gy per minute. Subsequently, one week later, we administered Mozobil [LP.] at 5 mg/kg dose followed by another Mozobil administration [5 mg/kg, I.P.] 48 hours later. We monitored the test mice for lesions relating to skin damage. We found skin damage was significantly reduced in mice receiving Mozobil.
- Skin damage to the hind leg of C57BL/6 mice was measured using a semi-quantitative scale (TABLE ONE).
-
TABLE ONE Semi Quantitative Scale For Evaluation Of The Lower Extremity Skin Reaction SCORE SKIN DAMAGE DESCRIPTION 1.0 No Effect. 1.5 Minimal erythema, mild dry skin. 2.0 Moderate Erythema, dry skin. 2.5 Marked erythema, start of dry desquamation. 3.0 Dry desquamation, start of skin breakdown, minimal dry crusting. 3.5 Dry desquamation, with dry crusting and superficial, minimal scabbing. 4.0 Patchy moist desquamation, moderate scabbing. 4.5 Confluent moist desquamation, ulcers, large deep scabs. 5.0 Open wound, draining, full thickness skin loss, necrosis. - Plerixafor given 7 days after the radiation exposure was highly effective at mitigating radiation cutaneous injury. A radiation exposure of 25 Gy caused chronic cutaneous injury characterized by dry desquamation and minimal scabbing that started at about 3 weeks and persisted to 60 days. When 25 Gy radiation exposure was followed by plerixafor (5 mg/kg, I.P.) given twice starting one week after the radiation exposure followed by another
dose 48 hours later, eighteen days after radiation the reaction was initially similar to radiation alone and soon resolved completely such that the legs were normal except for some hair thinning atday 60.FIG. 2A illustrates the effect at one month after 25 Gy exposure with and without plerixafor. - The response of mouse skin following 30 Gy plus plerixafor was even more dramatic (
FIG. 2B ). A radiation exposure of 30 Gy caused irreversible chronic cutaneous injury characterized by moist desquamation that started at about 3 weeks and persisted to 60 days. In contrast, mice receiving 30 Gy plus plerixafor (5 mg/kg, I.P.) given twice starting one week after the radiation exposure followed by anotherdose 48 hours later had some hair loss but were otherwise normal at approximatelyday 60. - Examples 3A and 3B (
FIGS. 2A and B) illustrate the mitigating effect of plerixafor as a function of time using the semi-quantitative scale of skin reaction described in Table 1. This data was used to approximate the radiation “protection” factor, RPF, defined as the radiation dose without mitigator necessary to obtain a biological effect divided by the radiation dose with the mitigator necessary to obtain the same biological effect. For mitigation of cutaneous injury in our model, plerixafor, appears to have a RPF of better than 1.2 since 25 Gy alone yielded a slightly worse biological response than did 30 Gy plus plerixafor. We conclude that the data is suggestive of a radiation protection factor of at least 1.2 (i.e. 30 Gy/25 Gy) when plerixafor followed radiation exposure by one week. - Leg contraction assessed by the percent leg extension relative to the unirradiated leg, another endpoint of normal tissue injury related to skin damage, was also significantly improved with the administration of plerixafor (data not shown).
- Referring to
FIG. 3 , skin cytokines by ELISA showed increasedlevels 30 days after a 30 Gy radiation exposure. There was a significant reduction compared to 30 Gy alone when irradiated mice were administered plerixafor (5 mg/kg, I.P.) onday 7 andday 9 after 30 Gy. Cytokine concentrations were from multiple samples, n=3 or 4 from single mice: one control, one receiving radiation alone and one receiving combined drug and radiation. - Our studies to date have shown that irradiated skin exhibits a significant increase in a number of cytokines including TGF-beta and TNF-alpha, which were significantly reduced by the addition of plerixafor (5 mg/kg, I.P. on
day FIG. 3 ). - The optimal results were found when the stem cell mobilizer was given starting 1 week after the radiation exposure.
- The magnitude of the effect was estimated. The dose of radiation resulting in a level of radiation skin injury in the presence of stem cell mobilizer, 30 Gy, was 1.2 times higher than the radiation dose resulting in the same effect in the absence of the stem cell mobilizer, 25 Gy, suggesting mice could tolerate 20% higher doses if administered stem cell mobilizer after the radiation exposure.
- Using an autologous spleen colony assay we observed improved bone marrow cell survival after a total body radiation exposure indicating that mobilized stem cells may have the ability to mitigate radiation injury in a variety of tissues following a radiation exposure.
- Accordingly, rapidly proliferating tissue such as bone marrow, skin and gastrointestinal tract are likely to benefit. This is significant because these tissues are known to be particularly susceptible to radiation injury. Other tissues which are slowly proliferating tissues such as lung and brain in which function can be preserved by a functioning subunit may be reconstituted by mobilized stem cells may also benefit from the approach.
- While the present invention has been particularly shown and described with reference to the foregoing preferred and alternative embodiments, it should be understood by those skilled in the art that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention without departing from the spirit and scope of embodiments of the invention as disclosed. It is intended that the method within the scope of these disclosures and their equivalents be covered thereby. This description of the invention should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in later applications to any novel and non-obvious combination of these elements. The foregoing embodiments are illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application.
- Where the disclosure recites “a” or “a first” element or the equivalent thereof, such disclosure should be understood to include incorporation of one or more such elements, neither requiring nor excluding two or more such elements.
Claims (13)
1. A method of mitigating radiation induced injury to a mammal that has been exposed to radiation, comprising the step of administering a pharmaceutically effective amount of a composition comprising at least one CXCR4 antagonist to the mammal.
2. The method of claim 1 wherein commencement of administration is effected at least 24 hours after exposure.
3. The method of claim 1 wherein commencement of administration is effected at least 48 hours after exposure.
4. The method of claim 1 wherein commencement of administration is effected at least 72 hours after exposure.
5. The method of claim 1 wherein commencement of administration is effected at least one week after exposure.
6. The method of claim 1 wherein commencement of administration is effected between 24 hours and one week after exposure.
7. The method of claim 1 wherein commencement of administration is effected between 48 hours and one week after exposure.
8. The method of claims 1 -7 wherein the mammal is a human.
9. The method of claims 1 -8 wherein the CXCR4 antagonist is AMD-3100.
10. The method of claims 1 -9 wherein the CXCR4 antagonist is coadmistered with a granulocyte colony-stimulating factor.
11. The method of claims 1 -10 wherein the method mitigates radiation induced injury to tissue.
12. The method of claim 11 wherein the method mitigates radiation induced injury to organ tissue.
13. The method of claim 12 wherein the method mitigates radiation induced injury to skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/504,585 US20130039882A1 (en) | 2009-10-28 | 2010-10-28 | Method to mitigate injury from radiation exposure |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25561909P | 2009-10-28 | 2009-10-28 | |
US13/504,585 US20130039882A1 (en) | 2009-10-28 | 2010-10-28 | Method to mitigate injury from radiation exposure |
PCT/US2010/054476 WO2011053700A1 (en) | 2009-10-28 | 2010-10-28 | Methods to mitigate injury from radiation exposure |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/054476 A-371-Of-International WO2011053700A1 (en) | 2009-10-28 | 2010-10-28 | Methods to mitigate injury from radiation exposure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/186,884 Continuation US20160303074A1 (en) | 2009-10-28 | 2016-06-20 | Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130039882A1 true US20130039882A1 (en) | 2013-02-14 |
Family
ID=43922537
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/504,585 Abandoned US20130039882A1 (en) | 2009-10-28 | 2010-10-28 | Method to mitigate injury from radiation exposure |
US15/186,884 Abandoned US20160303074A1 (en) | 2009-10-28 | 2016-06-20 | Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window |
US15/850,829 Active 2030-11-08 US10639296B2 (en) | 2009-10-28 | 2017-12-21 | Methods to mitigate injury from radiation exposure |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/186,884 Abandoned US20160303074A1 (en) | 2009-10-28 | 2016-06-20 | Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window |
US15/850,829 Active 2030-11-08 US10639296B2 (en) | 2009-10-28 | 2017-12-21 | Methods to mitigate injury from radiation exposure |
Country Status (4)
Country | Link |
---|---|
US (3) | US20130039882A1 (en) |
EP (1) | EP2493295A4 (en) |
IL (1) | IL219417B (en) |
WO (1) | WO2011053700A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130216531A1 (en) * | 2010-06-28 | 2013-08-22 | Rakesh K. Jain | Anti-cxcr4 as a sensitizer to cancer therapeutics |
US20160303074A1 (en) * | 2009-10-28 | 2016-10-20 | Henry Ford Health System | Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110613B (en) * | 2013-01-25 | 2014-10-22 | 中国人民解放军军事医学科学院野战输血研究所 | Application of saturated amine compound in preparation of anti-radiation damage medicament |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223180A1 (en) * | 2001-07-31 | 2006-10-05 | Anormed Inc. | Methods to mobilize progenitor/stem cells |
US20100055077A1 (en) * | 2007-01-09 | 2010-03-04 | Alexander Shakhov | Methods for increasing and mobilizing hematopoietic stem cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
CA2305787A1 (en) * | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
US7378098B2 (en) * | 2000-04-12 | 2008-05-27 | The University Of British Columbia | CXC chemokine receptor 4 agonist peptides |
CA2335109A1 (en) * | 2000-04-12 | 2001-10-12 | Chemokine Therapeutics Corporation | Cxcr4 agonist treatment of hematopoietic cells |
US6538030B2 (en) | 2000-09-20 | 2003-03-25 | Yih-Lin Chung | Treating radiation fibrosis |
JP2004537762A (en) | 2001-08-01 | 2004-12-16 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Gamma correction method and device |
AU2003226408B2 (en) | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
US6809118B2 (en) | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
US20060275370A1 (en) | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
WO2007047882A2 (en) * | 2005-10-18 | 2007-04-26 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Combination of cxcr4 antagonist and morphogen to increase angiogenesis |
EP2493295A4 (en) * | 2009-10-28 | 2013-05-08 | Ford Henry Health System | Methods to mitigate injury from radiation exposure |
-
2010
- 2010-10-28 EP EP10827469.7A patent/EP2493295A4/en not_active Withdrawn
- 2010-10-28 WO PCT/US2010/054476 patent/WO2011053700A1/en active Application Filing
- 2010-10-28 US US13/504,585 patent/US20130039882A1/en not_active Abandoned
-
2012
- 2012-04-25 IL IL219417A patent/IL219417B/en active IP Right Grant
-
2016
- 2016-06-20 US US15/186,884 patent/US20160303074A1/en not_active Abandoned
-
2017
- 2017-12-21 US US15/850,829 patent/US10639296B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060223180A1 (en) * | 2001-07-31 | 2006-10-05 | Anormed Inc. | Methods to mobilize progenitor/stem cells |
US20100055077A1 (en) * | 2007-01-09 | 2010-03-04 | Alexander Shakhov | Methods for increasing and mobilizing hematopoietic stem cells |
Non-Patent Citations (1)
Title |
---|
Wagemaker et al., "The Efficacy of Recombinant Thrombopoietin in Murine and Nonhuman Primate Models for Radiation-Induced Myelosuppression and Stem Cell Transplantation" Stem Cells (1998) vol. 16 pp. 375-386 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160303074A1 (en) * | 2009-10-28 | 2016-10-20 | Henry Ford Health System | Methods to mitigate injury from radiation exposure by administering cxcr4 antagonist during decisive treatment window |
US20130216531A1 (en) * | 2010-06-28 | 2013-08-22 | Rakesh K. Jain | Anti-cxcr4 as a sensitizer to cancer therapeutics |
US9155723B2 (en) * | 2010-06-28 | 2015-10-13 | The General Hospital Corporation | Anti-CXCR4 as a sensitizer to cancer therapeutics |
US20160128974A1 (en) * | 2010-06-28 | 2016-05-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
Also Published As
Publication number | Publication date |
---|---|
IL219417A0 (en) | 2012-06-28 |
IL219417B (en) | 2020-07-30 |
US20180193307A1 (en) | 2018-07-12 |
EP2493295A4 (en) | 2013-05-08 |
EP2493295A1 (en) | 2012-09-05 |
US10639296B2 (en) | 2020-05-05 |
US20160303074A1 (en) | 2016-10-20 |
WO2011053700A1 (en) | 2011-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Campolo et al. | AUTHOR COPY ONLY | |
US10639296B2 (en) | Methods to mitigate injury from radiation exposure | |
Chang et al. | Prevention and repair of circulatory shock and cerebral ischemia/injury by various agents in experimental heatstroke | |
Wang et al. | Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis | |
JP2022121544A (en) | Inorganic nitrite to improve cardiopulmonary hemodynamics | |
US9688724B2 (en) | Methods for limiting development of a skin wound | |
ES2702578T3 (en) | Treatment of chronic dermal inflammation with norketotifen | |
US11058655B2 (en) | Compositions and methods for treatment of inflammation | |
JP2008518020A (en) | How to promote wound healing | |
CN110613713B (en) | 3-hydroxyaminobenzoic acid and sorafenib combined medicine for treating tumor | |
JP2022536582A (en) | Use of an extract from rabbit skin inflamed by vaccinia virus in the treatment of hematopoietic injury | |
KR20150035276A (en) | Composition for Preventing and Treating Atopic Dermatitis Comprising Rapamycin and Mycophenolic acid | |
EP3426279B1 (en) | Treatment of hematopoietic stem cell transplant patients | |
KR20210039413A (en) | Combination therapy for the treatment of cancer | |
US20180243327A1 (en) | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE | |
US20230346880A1 (en) | Topical formulations for treatment of hypergranulation tissue | |
RU2457864C1 (en) | Gel possessing anti-inflammatory, immunotropic, antiallergic and wound healing action | |
US20230181661A1 (en) | Mushroom-containing chinese medicine compound composition for keloid scar tissue and application thereof | |
Shimizu et al. | Combination chemotherapy with 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride and bleomycin in meningeal carcinomatosis in rats | |
Pietraszkiewicz et al. | UTL-5g lowers levels of TGF-β and TNF-α elevated by lung irradiation and does not affect tumorresponse to irradiation | |
DE102007014752A1 (en) | Interleukin for use with human identical amino acid sequence and glycosyl residue for use as therapeutic agent for bacterial infections, sepsis, mycoplasma disease, autoimmune disease and multiple sclerosis in humans and animals | |
WO2023164298A2 (en) | Compositions and methods for protecting against cell damage and inflammation | |
AT511582B1 (en) | USE OF KEYHOLE-LIMPET-HEMOCYANINE OR COLD PRODUCTS THEREOF | |
JP2020535178A (en) | Use of secoisolariciresinol diglucoside (SDG) and related compounds for protection against radiation-induced cardiovascular disorders | |
WO2022103352A1 (en) | The use of intravenous immunoglobulin in the preparation of a drug for the treatment of cutis verticis gyrata disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HENRY FORD HEALTH SYSTEM, MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, JAE HO;BROWN, STEPHEN L.;KOLOZSVARY, ANDREW;SIGNING DATES FROM 20120914 TO 20120919;REEL/FRAME:029026/0398 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |